It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.

On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.

When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?

US-listed Chinese biotechs face a potential double-whammy from US rules requiring accounting transparency at the risk of delisting, while other challenges loom from a general regulatory crackdown and economic softening in China, along with rising COVID-19 cases.